	Application No.	Applicant(s)
Notice of Allowability	10/053,662	BAIRD ET AL.
	Examiner	Art Unit
	Robert A. Wax	1653
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to the amendment filed November 4, 2003.		
2. The allowed claim(s) is/are 12-15,19 and 21.		
3. The drawings filed on are accepted by the Examiner.		
4. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some* c) None of the: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)). * Certified copies not received: Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 5. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient. 6. CORRECTED DRAWINGS (as "replacement sheets") must be submitted. (a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached 1) hereto or 2) to Paper No./Mail Date (b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d). 7. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s) 1. ☐ Notice of References Cited (PTO-892) 2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-94) 3. ☐ Information Disclosure Statements (PTO-1449 or PTO/S Paper No./Mail Date 4. ☐ Examiner's Comment Regarding Requirement for Depose of Biological Material	8) 6. ⊠ Interview S Paper No B/08), 7. ⊠ Examiner's	nformal Patent Application (PTO-152) Summary (PTO-413), ./Mail Date <u>02032004</u> . s Amendment/Comment s Statement of Reasons for Allowance
		Robert A. Wax Primary Examiner Art Unit: 1653

Application/Control Number: 10/053,662

Art Unit: 1653

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes 1. and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Susan Tandan on February 3, 2004.

2. The application has been amended as follows:

Cancel claims 1-11, 16-18 and 20.

Amend claim 12, part 3): delete "position 1368" and substitute therefor - - -a position corresponding to position 1368 of SEQ ID No. 1---.

Add the following new claim:

- 21. The method of claim 12 wherein the mutated laminin γ2-encoding nucleic acid has a cytosine insert at position 1368 of SEQ ID No. 1.
- The following is an examiner's statement of reasons for allowance: Tryggvason 3. et al. do not teach the mutation at position 1368 of SEQ ID No. 1 as diagnostic of epidermolysis bullosa; they teach other mutations instead. The language "a position corresponding to position 1368 of SEQ ID No. 1" in claim 1 is intended to encompass sequences not exactly identical to SEQ ID No. 1 that still encode laminin y2 within the

Art Unit: 1653

scope of the claims. This recognizes the fact that different animals have differing sequences of proteins and DNA that still exhibit the corresponding functions; an example of this is an allelic variant.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

4. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Robert A. Wax whose telephone number is (571) 272-0623. The examiner can normally be reached on Monday through Friday, between 9:00 AM and 5:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christopher S. F. Low can be reached on (571) 272-0951. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Robert A. Wax Primary Examiner Art Unit 1653